The drug regulator has declined to approve the extended-release formulation of GlaxoSmithKline's epilepsy pill Lamictal, claiming that further analyses of previously submitted data are needed for its approval, a company spokeswoman said. The company says it anticipates generic competition for the drug by January 2009.

Full Story:

Related Summaries